Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern

• Status: Unknown status
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Controlled ovarian stimulation (COS) for FIV increases progesterone (P) and estradiol (E2) serum levels in supraphysiologic concentrations at the end of follicular phase. Elevated serum P levels leads to an accelerated endometrial maturation which interferes with the dialogue between embryo and endometrium. It has been reported that serum progesterone levels ≥ 1.5 ng/ml on the last day of COS are related to a significant decrease in the ongoing pregnancy rate following IVF cycles. Also, it has been reported a significant alteration in the endometrial gene expression profile related to P elevated levels.

Glycodelin-A is an immunomodulatory glycoprotein synthesized by luteal-phase endometrial epithelium and its expression seems to be related to the action of P. Because glycodelin-A has immunosuppressive activity, it may facilitate the process of implantation and the maintenance of pregnancy.

It is already know that ulipristal acetate (UPA) decrease serum P levels. The hypothesis of this study is that UPA is been able to modify P serum levels and glycodelin-A endometrial expression pattern on FSH/GnRH Antagonist cycles for FIV.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Programa de Asistencia Reproductiva de Rosario
• Treatments: Progesterone; Ulipristal acetate

Criteria

Inclusion Criteria:

• Age <35 years old

• FSH on day 3: <12 UI/ml

• Antral follicular count ≥ 6 on day 3 of the cycle

• BMI: <30 Kg/m2

Exclusion Criteria:

• Hypothyroidism

• Hyperprolactinemia

• Kidney or liver disease

• Smoking

• Alcoholism